Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

Direct Payment

$150,000.00

Metabolic and Epigenetic Reprogramming in Liver Cancer

FY 2011-12

Summary
There is an immediate and critical need for improved strategies to treat biliary cancer, a tumor type for which most patients die within one year of diagnosis. In recent years a new era of targeted molecular therapeutics has emerged for treating cancer. This new generation of targeted therapies is more effective, less toxic and can produce dramatic clinical responses in a subset of treated patients. The clinical response to a particular targeted agent is dependent on specific genetic abnormalities within an individual's tumor. New targeted therapies can block these specific cancer-driving pathways and thereby exploit the tumor's vulnerability. In this regard, mutations have recently been detected in enzymes called IDH1 and IDH2 that regulate pathways by which the cell produces energy and the building blocks for multiple cellular processes. Thus the identification of these mutations provides a completely new model of how basic metabolic processes gone awry can lead to cancer development. Understanding in depth how mutations in these genes cause biliary cancer and identifying ways to specifically kill cancer cells harboring these mutations are key challenges in developing improved approaches to managing these cancers. My project will involve the study of novel genetically engineered mouse models to determine how these mutations function in driving cancer development, and to test whether these mutations are critical in sustaining the growth of advanced cancers. I will also use new genetic technologies that will allow me to identify additional biochemical pathways that are abnormal in IDH mutant cancer cells and that therefore are potential new drug targets. Overall, these studies will define distinct subgroups of biliary cancer, provide new insights into cancer therapeutics, and directly inform the design of refined clinical trials.
Program
CIHR Fellowship
Location
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
255989
Name
Parachoniak Christine A
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Metabolic and Epigenetic Reprogramming in Liver Cancer
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Cell Metabolism; Epigenetics; Genetically Engineered Mouse Models; Liver Cancer; Metabolic Enzymes; Molecular Biology; Rnai Screen; Tissue/Cell Culture
Abstract
There is an immediate and critical need for improved strategies to treat biliary cancer, a tumor type for which most patients die within one year of diagnosis. In recent years a new era of targeted molecular therapeutics has emerged for treating cancer. This new generation of targeted therapies is more effective, less toxic and can produce dramatic clinical responses in a subset of treated patients. The clinical response to a particular targeted agent is dependent on specific genetic abnormalities within an individual's tumor. New targeted therapies can block these specific cancer-driving pathways and thereby exploit the tumor's vulnerability. In this regard, mutations have recently been detected in enzymes called IDH1 and IDH2 that regulate pathways by which the cell produces energy and the building blocks for multiple cellular processes. Thus the identification of these mutations provides a completely new model of how basic metabolic processes gone awry can lead to cancer development. Understanding in depth how mutations in these genes cause biliary cancer and identifying ways to specifically kill cancer cells harboring these mutations are key challenges in developing improved approaches to managing these cancers. My project will involve the study of novel genetically engineered mouse models to determine how these mutations function in driving cancer development, and to test whether these mutations are critical in sustaining the growth of advanced cancers. I will also use new genetic technologies that will allow me to identify additional biochemical pathways that are abnormal in IDH mutant cancer cells and that therefore are potential new drug targets. Overall, these studies will define distinct subgroups of biliary cancer, provide new insights into cancer therapeutics, and directly inform the design of refined clinical trials.
Competitiondate
201202
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Parachoniak, Christine A
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~
Direct Payment - $150,000 Grant (2011-12) | Canada Spends